Antibiotics, infection and patients who share hospital beds

Researchers have found that infections from Clostridium difficile (CDI), a bacterium that causes diarrhea and serious intestinal conditions such as colitis, can pass from patient to patient after sharing the same hospital bed.

A team of researchers led by Daniel E. Freedberg, MD, MS, set out to assess whether giving antibiotics to patients in a specific hospital bed will have an effect on CDI rates in patients who use the bed next. To control the spread of CDI, researchers conducted a study of patients hospitalized in one of four facilities between 2010 and 2014.

The study contained 100,615 pairs of patients who shared a hospital bed after one another. Of the participants, 576 pairs contracted CDI, which is a rate of 0.57 percent. Patients who had received antibiotics were much more likely to pass CDI to the patients using the bed after them. This pattern remained unchanged by other factors that were also known to influence the risk of CDI.

“These data imply that patient-to-patient transmission of C difficile or other bacteria that mediate susceptibility to CDI takes place in the non-outbreak setting and in the face of a multifaceted effort seeking to prevent health care–associated CDI,” wrote Freedberg and colleagues. “More generally, these data support the hypothesis that antibiotics given to one patient may alter the local microenvironment to influence a different patient’s risk for CDI.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.